Document 2676 DOCN M94A2676 TI Risk factors for HIV seroconversion among injecting drug users in Montreal: the Saint-Luc cohort experience. DT 9412 AU Lamothe F; Bruneau J; Soto J; Lachance N; Franco E; Vincelette J; Fauvel M; Hopital Saint-Luc, Canada. SO Int Conf AIDS. 1994 Aug 7-12;10(1):25 (abstract no. 074C). Unique Identifier : AIDSLINE ICA10/94369899 AB OBJECTIVES: To evaluate HIV seroconversion rates and risk factors in an open dynamic cohort of injecting drug users (IDUs) in Montreal. METHODS: Consenting IDUs (all recent injectors) were recruited from the street and treatment centers in a follow-up cohort. Information and HIV serology were obtained at each visit. Univariate actuarial analysis of seroconversion was performed using Kaplan-Meier life time estimators. RESULTS: From 1988/9 to 1993/2, 55 of 608 negative subjects seroconverted. Total follow-up was 874 person-years for an incidence rate per 100 person-years of 6.3% (95% IC: 4.7-8.2). For 3 consecutive 18 months periods, incidence rose from 4.8% (88/9-90/2), 7.5% (90/3-91/8) to 9.8% (after 91/9) (p = 0.046, Log-rank test). Entry factors associated with conversion were: street recruitment, previous imprisonment, cocaine preference, more than 15 injections (last 28 days), attending a needle exchange program at least once, 2 or more sharing partners, sharing with an HIV+/AIDS partner, and having HIV+/AIDS acquaintances (all p < 0.05, Log-rank test). Factors not associated were: sex, booting fresh blood, injecting in shooting galleries, sexual orientation, prostitution and number of sexual partners. CONCLUSION: HIV infection seems to progress among IDUs recruited. Seroconversion is associated with needle sharing behaviours in spite of risk knowledge and relative availability of sterile equipment. More research is needed on impulsive determinants of sharing behaviours. DE Actuarial Analysis Cohort Studies Female Human HIV Infections/TRANSMISSION HIV Seropositivity/*EPIDEMIOLOGY Incidence Male Needle Sharing Quebec/EPIDEMIOLOGY Risk Factors Sex Behavior Substance Abuse, Intravenous/*COMPLICATIONS MEETING ABSTRACT SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).